Adipose depot-specific effects of 16 weeks of pioglitazone on in vivo adipogenesis in women with obesity: a randomised controlled trial is a research paper published in Diabetologia (2020). On theSindex it has a DataRank of 1.8. It has been cited 43 times, with 34 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.568
From this paper's citation signal
Citation Network Contribution
1.2
From 32 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 34 citers.
National Institute of General Medical Sciences
Grant: U54 GM104940
National Institute of Diabetes and Digestive and Kidney Diseases
Grant: R03DK112006
NIDDK NIH HHS
Grant: R01 DK090607
NIDDK NIH HHS
Grant: P30 DK072476
NIDDK NIH HHS
Grant: R01 DK121944
National Institutes of Health
Grant: 3U54GM104940-07S3
Louisiana Clinical and Translational Science Center Supplement - COVID Sequence Surveillance Network
National Institutes of Health
Grant: 5R01DK090607-02
Cellular Dynamics of Subcutaneous Fat Distribution in Obese Women
National Institutes of Health
Grant: 5R03DK112006-02
Depot-specific adipose cell size distributions and metabolic health markers
National Institutes of Health
Grant: 5P30DK072476-05
Core--Molecular Mechanisms
FWCI
3.99
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 1 of Effects of half-dose spiomet treatment in girls with early puberty and accelerated bone maturation: a multicenter, randomized, placebo-controlled study protocol
Additional file 1 of Effects of half-dose spiomet treatment in girls with early puberty and accelerated bone maturation: a multicenter, randomized, placebo-controlled study protocol
Additional file 1 of SPIOMET4HEALTH—efficacy, tolerability and safety of lifestyle intervention plus a fixed dose combination of spironolactone, pioglitazone and metformin (SPIOMET) for adolescent girls and young women with polycystic ovary syndrome: study protocol for a multicentre, randomised, double-blind, placebo-controlled, four-arm, parallel-group, phase II clinical trial
Additional file 1 of SPIOMET4HEALTH—efficacy, tolerability and safety of lifestyle intervention plus a fixed dose combination of spironolactone, pioglitazone and metformin (SPIOMET) for adolescent girls and young women with polycystic ovary syndrome: study protocol for a multicentre, randomised, double-blind, placebo-controlled, four-arm, parallel-group, phase II clinical trial
Additional file 2 of SPIOMET4HEALTH—efficacy, tolerability and safety of lifestyle intervention plus a fixed dose combination of spironolactone, pioglitazone and metformin (SPIOMET) for adolescent girls and young women with polycystic ovary syndrome: study protocol for a multicentre, randomised, double-blind, placebo-controlled, four-arm, parallel-group, phase II clinical trial
Additional file 2 of SPIOMET4HEALTH—efficacy, tolerability and safety of lifestyle intervention plus a fixed dose combination of spironolactone, pioglitazone and metformin (SPIOMET) for adolescent girls and young women with polycystic ovary syndrome: study protocol for a multicentre, randomised, double-blind, placebo-controlled, four-arm, parallel-group, phase II clinical trial